Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation.

Over the last six months, Otis’s shares have sunk to $87.81, producing a disappointing 9.9% loss - a stark contrast to the S&P 500’s 12.9% gain. This may have investors wondering how to approach the ...

Keeping my Buy rating on Energy Transfer LP, supported by an already normalized valuation and a compelling 8.5% forward yield ...

Use a days calculator to track GST, ITR, TDS, and ROC deadlines in India. Calculate exact days for tax compliance and avoid ...

Accenture has entered into an agreement with the Fibonacci Group to acquire Cabel Industry, an Italian technology company ...